Half-year report · HY
9265.TEDINET S100XEU8
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.6bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥64.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.4bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | ¥216m | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥522m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥297m | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥909m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥552m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥295m | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥586m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥134m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥616m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥338m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥133m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | ¥337m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥26.0bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥26.4bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.0bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥18.6bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.9bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥9.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.7bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.3bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.4bn | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥617m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥633m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥615m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥19m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥19m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥337m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥240m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥239m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥53.28 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥249.79 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.8 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.3% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.6% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-06-01 → 2025-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2025-11-30 | −¥510m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥104m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥104m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2025-06-01 → 2025-11-30 | −¥111m |
| Medical Equipment Salesreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥30.5bn |
| Medical Equipment Salesreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥30.5bn |
| Medical Equipment Salesreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥834m |
| Medical Mallreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥36m |
| Medical Mallreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥36m |
| Medical Mallreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥4m |
| —segment total | revenue | 2025-06-01 → 2025-11-30 | ¥30.6bn |
| —segment total | revenue external | 2025-06-01 → 2025-11-30 | ¥30.6bn |
| —segment total | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥0 |
| —segment total | segment profit | 2025-06-01 → 2025-11-30 | ¥727m |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥519m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥113m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥112m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥82m |
| Medical Equipment Salesreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥31.2bn |
| Medical Equipment Salesreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥31.2bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥1.1bn |
| Medical Mallreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥35m |
| Medical Mallreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥35m |
| Medical Mallreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥0 |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥31.4bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥31.4bn |
| —segment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 487
| Item | Context | Value | Unit |
|---|---|---|---|
| Current liabilities | Prior1YearInstant | 18087000000 | JPY |
| Current liabilities | InterimInstant | 16556000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 58000000 | JPY |
| Net defined benefit liability | InterimInstant | 57000000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 45000000 | JPY |
| Deferred tax liabilities | InterimInstant | 87000000 | JPY |
| Other ncl | Prior1YearInstant | 368000000 | JPY |
| Other ncl | InterimInstant | 348000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 472000000 | JPY |
| Noncurrent liabilities | InterimInstant | 493000000 | JPY |
| Liabilities | Prior1YearInstant | 18560000000 | JPY |
| Liabilities | InterimInstant | 17049000000 | JPY |
| Capital stock | Prior1YearInstant | 494000000 | JPY |
| Capital stock | InterimInstant | 494000000 | JPY |
| Capital surplus | Prior1YearInstant | 627000000 | JPY |
| Capital surplus | InterimInstant | 594000000 | JPY |
| Retained earnings | Prior1YearInstant | 7206000000 | JPY |
| Retained earnings | InterimInstant | 7155000000 | JPY |
| Treasury stock | Prior1YearInstant | -231000000 | JPY |
| Treasury stock | InterimInstant | -186000000 | JPY |
| Shareholders equity | Prior1YearInstant | 8096000000 | JPY |
| Shareholders equity | InterimInstant | 8058000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 637000000 | JPY |
| Valuation difference on available for sale securities | InterimInstant | 636000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 242000000 | JPY |
| Remeasurements of defined benefit plans | InterimInstant | 217000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 879000000 | JPY |
| Valuation and translation adjustments | InterimInstant | 854000000 | JPY |
| Non controlling interests | Prior1YearInstant | 11000000 | JPY |
| Non controlling interests | InterimInstant | － | JPY |
| Net assets | Prior1YearInstant | 8988000000 | JPY |
| Net assets | InterimInstant | 8912000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 27549000000 | JPY |
| Liabilities and net assets | InterimInstant | 25961000000 | JPY |
| Net sales | Prior1InterimDuration | 31362000000 | JPY |
| Net sales | InterimDuration | 30645000000 | JPY |
| Cost of sales | Prior1InterimDuration | 27157000000 | JPY |
| Cost of sales | InterimDuration | 26610000000 | JPY |
| Gross profit | Prior1InterimDuration | 4205000000 | JPY |
| Gross profit | InterimDuration | 4034000000 | JPY |
| Selling general and administrative expenses | Prior1InterimDuration | 3683000000 | JPY |
| Selling general and administrative expenses | InterimDuration | 3818000000 | JPY |
| Operating income | Prior1InterimDuration | 522000000 | JPY |
| Operating income | InterimDuration | 216000000 | JPY |
| Interest and dividends income noi | Prior1InterimDuration | 6000000 | JPY |
| Interest and dividends income noi | InterimDuration | 8000000 | JPY |
| Purchase discounts noi | Prior1InterimDuration | 7000000 | JPY |
| Purchase discounts noi | InterimDuration | 7000000 | JPY |
| Commission fee noi | Prior1InterimDuration | 12000000 | JPY |
| Commission fee noi | InterimDuration | 13000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |